FDA Approved Products

1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
Active:Lifecycle: PeakClear all
DOCETAXEL
docetaxel
Peak
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2012
NDA
30/100
DOCETAXEL
docetaxel
Peak
Accord Biopharma
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2011
NDA
30/100
DOTAREM
gadoterate meglumine
Peak
Guerbet
INTRAVENOUS · SOLUTION
2013
NDA
30/100
DOXERCALCIFEROL
doxercalciferol
Peak
Pfizer
INJECTION · INJECTABLE
secondary hyperparathyroidism in adult patients with Stage 3Stage 4 chronic kidney disease (CKD)+1
2018
NDA
30/100
DRAX EXAMETAZIME
kit for the preparation of technetium tc 99m exametazime for leukocyte labeling
Peak
Jubilant Therapeutics
INTRAVENOUS · POWDER
2017
NDA
30/100
DUOPA
carbidopa and levodopa
Peak
AbbVie
ENTERAL · SUSPENSION
motor fluctuations in patients with advanced Parkinson's disease ()Parkinson's disease
2015
NDA
30/100
DURLAZA
aspirin
Peak
ORAL · CAPSULE, EXTENDED RELEASE
deathmyocardial infarction (MI) in patients with chronic coronary artery disease+8
2015
NDA
30/100
E-Z-CAT DRY
barium sulfate
Peak
Bracco
ORAL · FOR SUSPENSION
2016
NDA
30/100
E-Z-HD
barium sulfate
Peak
Bracco
ORAL · FOR SUSPENSION
2016
NDA
30/100
E-Z-PAQUE
barium sulfate
Peak
Bracco
ORAL · FOR SUSPENSION
2016
NDA
30/100
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
efavirenz; lamivudine; tenofovir disoproxil fumarate
Peak
ORAL · TABLET
2019
NDA
30/100
EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE
efavirenz; lamivudine; tenofovir disoproxil fumarate
Peak
ORAL · TABLET
2018
NDA
30/100
EGATEN
triclabendazole
Peak
Novartis
ORAL · TABLET
fascioliasis in patients 6 years of ageolder
2019
SMNDA
30/100
EMFLAZA
deflazacort
Peak
PTC Therapeutics
ORAL · TABLET
Duchenne muscular dystrophy (DMD) in patients 2 years of ageolder ()
2017
NDA
30/100
EMFLAZA
deflazacort
Peak
PTC Therapeutics
ORAL · SUSPENSION
Duchenne muscular dystrophy (DMD) in patients 2 years of ageolder ()
2017
NDA
30/100
ENDARI
glutamine
Peak
Emmaus Life Sciences
ORAL · FOR SOLUTION
acute complications of sickle cell disease in adultolder
2017
NDA
30/100
ENTADFI
finasteride; tadalafil
Peak
ORAL · CAPSULE
2021
NDA
30/100
ENTERO VU 24%
barium sulfate
Peak
Bracco
ORAL · SUSPENSION
2016
NDA
30/100
EPHEDRINE SULFATE
ephedrine sulfate
Peak
INTRAVENOUS · SOLUTION
clinically important hypotension occurring in the setting of anesthesia
2017
NDA
30/100
EPIDUO FORTE
adapalene and benzoyl peroxide
Peak
Galderma
TOPICAL · GEL
2015
NDA
30/100
EPINEPHRINE
epinephrine
Peak
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
To increase mean arterial blood pressure
2014
NDA
30/100
EPINEPHRINE
epinephrine
Peak
Medica Corp
INTRAVENOUS · SOLUTION
2022
NDA
30/100
EPINEPHRINE
epinephrine
Peak
Pfizer
INTRAVENOUS · SOLUTION
regional anesthesiaanalgesia for surgery+5
2019
NDA
30/100
ESOMEPRAZOLE STRONTIUM
esomeprazole strontium
Peak
R-Pharm US
ORAL · CAPSULE, DELAYED RELEASE
2013
NDA
30/100
← PreviousPage 5 of 55Next →